UCLA Magnesium Formulation Athlete Study

Part of paid clinical trials in Los Angeles, California.

Sponsor
University of California, Los Angeles
Study ID
NCT07640685
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Athletic Performance
  • Recovery
  • Sleep

Eligibility Criteria

Sex
ALL
Age
18 Years - 35 Years
Healthy Volunteers
Accepted

Interventions

  • Magnesium glycinate — DIETARY_SUPPLEMENT
    Blinded oral magnesium glycinate capsules taken nightly for 28 days.
  • Magnesium L-threonate — DIETARY_SUPPLEMENT
    Blinded oral magnesium L-threonate capsules taken nightly for 28 days.
  • Placebo — OTHER
    Matching placebo capsules taken nightly for 28 days.

Study Details

This randomized, double-blind, placebo-controlled trial will compare magnesium glycinate, magnesium L-threonate, and placebo in UCLA varsity athletes. Participants will complete a baseline monitoring period followed by 4 weeks of blinded nightly supplementation. WHOOP or study-approved wearable data will be used to evaluate sleep efficiency, total sleep time, sleep consistency, heart rate variability, resting heart rate, and recovery metrics. Baseline and final testing will assess selected reaction and physical performance outcomes. The primary outcome is change in WHOOP-derived sleep efficiency from baseline week to final treatment week.

Key Dates

Start date
Jul 31, 2026
Status verified
Jun 2026
Primary completion
May 31, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
150 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Experimental: Magnesium Glycinate
    Participants randomized to this arm will take blinded magnesium glycinate capsules nightly for 4 weeks. The current planning dose is approximately 240 mg elemental magnesium nightly, with final capsule count and label language based on the selected blinded formulation.
  • Experimental: Magnesium L-Threonate
    Participants randomized to this arm will take blinded magnesium L-threonate capsules nightly for 4 weeks. The current planning target is approximately 2 g/day total magnesium L-threonate, with elemental magnesium content, capsule count, and label language confirmed before activation.
  • Placebo Comparator: Placebo
    Participants randomized to this arm will take matching placebo capsules nightly for 4 weeks on the same blinded schedule.

Primary Outcome Measure

Change in WHOOP-derived sleep efficiency percentage from baseline week to final treatment week [ Time Frame: Baseline week to final treatment week, approximately 5 weeks total including baseline monitoring ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, Los AngelesLos AngelesCalifornia90095
Jeremy Swisher, MD
[email protected]
936-520-3595
Kimberly Burbank, MD
[email protected]

Find similar trials in Los Angeles, CA

By research site
University of California, Los Angeles· Los Angeles, CA

Related Studies